Quintrio
Home

Stock overview

Sol-Gel Technologies Ltd. Ordinary Shares

SLGL

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

Last trade $51.89
Day change -$3.07 (-5.59%)
Day range $51.34 – $57.85
Volume 41,414
Market cap $180M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SLGL.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SLGL, quarterly periods
Line itemQ2 FY2020 Jun 30, 2020Q2 FY2019 Jun 30, 2019
Revenue$1.13M$7.79M
Cost of revenue$0$0
Gross profit$1.13M$7.79M
Selling, general and administrative$2.23M$1.64M
Research and development$6.45M$11.44M
Total operating expenses$8.68M$13.08M
Operating income-$7.55M-$5.29M
Interest expense——
Income before taxes-$7.07M-$4.93M
Income taxes——
Net income-$7.07M-$4.93M
Net income attributable to common shareholders-$7.07M-$4.93M
EBITDA-$7.55M-$5.29M
Basic earnings per share-$3.10-$2.60
Diluted earnings per share-$3.10-$2.60

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Supernus Pharmaceuticals beat Q3 2026 earnings expectations with $0.93 EPS versus consensus of $0.49, representing an 89.80% surprise. Revenue of $226.77 million also exceeded estimates by 1.39%. However, the stock has underperformed the market by 17.3% year-to-date and carries a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends ahead of the earnings release.

Zacks Investment Research

New Strong Buy Stocks for October 16th

Zacks has added five stocks to its Strong Buy list based on increasing consensus earnings estimates over the last 60 days. The stocks span energy, technology distribution, immuno-oncology, biopharmaceutical, and chemical manufacturing sectors, with earnings estimate increases ranging from 3.5% to 30.6%.

Zacks Investment Research

SolGel Technologies (SLGL) Upgraded to Buy: Here's Why

Sol-Gel Technologies Ltd. (SLGL) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's Zacks Consensus Estimate has increased 41.9% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.

GlobeNewswire Inc.

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

Sol-Gel Technologies Ltd. (NASDAQ: SLGL) announced the pricing of an underwritten offering of 459,112 ordinary shares at $72.00 per share, generating approximately $33.1 million in gross proceeds. The offering, expected to close on March 25, 2026, includes participation from multiple institutional investors. Net proceeds will fund continued development of SGT-610, a Phase 3 topical hedgehog inhibitor for basal cell carcinoma prevention in Gorlin syndrome patients, along with working capital and general corporate purposes.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 5, 20251-for-10reverse split